pembrolizumab
merck
['keynote,91']
dr. presents pd-l1 subgroup analysis from ph 3 randomized keynote-091 trial at #esmo22 
Thoracic Medical Oncologist @lombardicancer, Assistant Professor @Georgetown. Interested in immunotherapy translational clinical trials. Opinions are my own.